If approved, ABBV-951 could be an alternative to oral therapy – whose efficacy tends to fall off over time – as well as sustained delivery approaches such as AbbVie's own Duopa, a form of ...

AbbVie already sells another long-acting treatment called Duopa, which delivers carbidopa and levodopa in an intestinal gel form via a gastric tube and pump, but that requires a surgical procedure ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb. 14. That is almost 6% higher than the prior payout. The company ...

AbbVie has signed a licensing deal with Danish-based Gubra to develop an obesity drug, marking the North Chicago company's first foray into the obesity market. Gubra will receive $350 million ...